Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 429706, 10 pages
http://dx.doi.org/10.1155/2013/429706
Research Article

Emu Oil Reduces Small Intestinal Inflammation in the Absence of Clinical Improvement in a Rat Model of Indomethacin-Induced Enteropathy

1Department of Gastroenterology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia
2Discipline of Physiology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA 5005, Australia
3School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, Roseworthy, SA 5371, Australia

Received 28 November 2012; Revised 4 February 2013; Accepted 13 February 2013

Academic Editor: Roci­o De la Puerta

Copyright © 2013 Suzanne M. Abimosleh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. A. Green, “Understanding NSAIDs: from aspirin to COX-2,” Clinical Cornerstone, vol. 3, no. 5, pp. 50–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Kamil, M. S. Geier, R. N. Butler, and G. S. Howarth, “Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy,” Digestive Diseases and Sciences, vol. 52, no. 5, pp. 1247–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Scarpignato, “NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?” Gut, vol. 57, no. 2, pp. 145–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Hawcroft, M. D'Amico, C. Albanese, A. F. Markham, R. G. Pestell, and M. A. Hull, “Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells,” Carcinogenesis, vol. 23, no. 1, pp. 107–114, 2002. View at Google Scholar · View at Scopus
  5. U. A. Boelsterli, M. R. Redinbo, and K. S. Saitta, “Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies,” Toxicological Sciences, vol. 131, no. 2, pp. 654–667, 2012. View at Publisher · View at Google Scholar
  6. C. Scarpignato and R. H. Hunt, “Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention,” Gastroenterology Clinics of North America, vol. 39, no. 3, pp. 433–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. B. K. Reuter, N. M. Davies, and J. L. Wallace, “Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation,” Gastroenterology, vol. 112, no. 1, pp. 109–117, 1997. View at Google Scholar · View at Scopus
  8. S. Somasundaram, G. Sigthorsson, R. J. Simpson et al., “Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 5, pp. 639–650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Lanas and C. Scarpignato, “Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?” Digestion, vol. 73, supplement 1, pp. 136–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Fukumoto, Y. Naito, T. Takagi et al., “Role of tumor necrosis factor-α in the pathogenesis of indomethacin-induced small intestinal injury in mice,” International Journal of Molecular Medicine, vol. 27, no. 3, pp. 353–359, 2011. View at Publisher · View at Google Scholar
  11. K. Takeuchi, M. Tanigami, K. Amagase, A. Ochi, S. Okuda, and R. Hatazawa, “Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors,” Journal of Gastroenterology and Hepatology, vol. 25, supplement 1, pp. S67–S74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Takeuchi, A. Tanaka, S. Kato, K. Amagase, and H. Satoh, “Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage,” Clinica Chimica Acta, vol. 411, no. 7-8, pp. 459–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Patrignani, S. Tacconelli, M. G. Sciulli, and M. L. Capone, “New insights into COX-2 biology and inhibition,” Brain Research Reviews, vol. 48, no. 2, pp. 352–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Sigthorsson, R. J. Simpson, M. Walley et al., “COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice,” Gastroenterology, vol. 122, no. 7, pp. 1913–1923, 2002. View at Google Scholar · View at Scopus
  15. Y. Maehata, M. Esaki, T. Morishita et al., “. Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam,” Journal of Gastroenterology, vol. 47, no. 4, pp. 387–393, 2012. View at Publisher · View at Google Scholar
  16. L. Maiden, B. Thjodleifsson, A. Seigal et al., “Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study,” Clinical Gastroenterology and Hepatology, vol. 5, no. 9, pp. 1040–1045, 2007. View at Google Scholar · View at Scopus
  17. E. A. Miles and P. C. Calder, “Influence of marine n3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis,” The British Journal of Nutrition, 2, pp. S171–S184, 2012. View at Publisher · View at Google Scholar
  18. D. Tenikoff, K. J. Murphy, M. Le, P. R. Howe, and G. S. Howarth, “Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease,” Journal of Gastroenterology, vol. 40, no. 4, pp. 361–365, 2005. View at Google Scholar · View at Scopus
  19. C. J. Lo, K. C. Chiu, M. Fu, R. Lo, and S. Helton, “Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NFκB activity,” Journal of Surgical Research, vol. 82, no. 2, pp. 216–221, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Khalfoun, F. Thibault, H. Watier, P. Bardos, and Y. Lebranchu, “Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6,” Advances in Experimental Medicine and Biology, vol. 400, pp. 589–597, 1997. View at Google Scholar · View at Scopus
  21. R. De Caterina and P. Libby, “Control of endothelial leukocyte adhesion molecules by fatty acids,” Lipids, vol. 31, no. 3, pp. S-57–S-63, 1996. View at Google Scholar · View at Scopus
  22. C. V. Whiting, P. W. Bland, and J. F. Tarlton, “Dietary n3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis,” Inflammatory Bowel Diseases, vol. 11, no. 4, pp. 340–349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Abimosleh, C. D. Tran, and G. S. Howarth, “Emu oil: a novel therapeutic for disorders of the gastrointestinal tract?” Journal of Gastroenterology and Hepatology, vol. 27, no. 5, pp. 857–861, 2012. View at Publisher · View at Google Scholar
  24. S. M. Abimosleh, R. J. Lindsay, R. N. Butler et al., “Emu oil increases colonic crypt depth in a rat model of ulcerative colitis,” Digestive Diseases and Sciences, vol. 57, no. 4, pp. 887–896, 2012. View at Publisher · View at Google Scholar
  25. M. W. Whitehouse, A. G. Turner, C. K. C. Davis, and M. S. Roberts, “Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine,” Inflammopharmacology, vol. 6, no. 1, pp. 1–8, 1998. View at Google Scholar · View at Scopus
  26. J. M. Snowden and M. W. Whitehouse, “Anti-inflammatory activity of emu oils in rats,” Inflammopharmacology, vol. 5, no. 2, pp. 127–132, 1997. View at Google Scholar · View at Scopus
  27. S. Yoganathan, R. Nicolosi, T. Wilson et al., “Antagonism of croton oil inflammation by topical emu oil in CD-1 mice,” Lipids, vol. 38, no. 6, pp. 603–607, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. J. Lindsay, M. S. Geier, R. Yazbeck, R. N. Butler, and G. S. Howarth, “Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis,” British Journal of Nutrition, vol. 104, no. 4, pp. 513–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. F. M. Tomas, S. E. Knowles, P. C. Owens et al., “Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats,” Journal of Endocrinology, vol. 128, no. 1, pp. 97–105, 1991. View at Google Scholar · View at Scopus
  30. R. Portolesi, B. C. Powell, and R. A. Gibson, “Competition between 24:5n3 and ALA for Δ6 desaturase may limit the accumulation of DHA in HepG2 cell membranes,” Journal of Lipid Research, vol. 48, no. 7, pp. 1592–1598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. N. S. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergran, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722–1734, 1993. View at Google Scholar · View at Scopus
  32. G. S. Howarth, C. J. Xian, and L. C. Read, “Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-I for twenty weeks in a rat model of chronic inflammatory bowel disease,” Growth Factors, vol. 18, no. 2, pp. 119–133, 2000. View at Google Scholar · View at Scopus
  33. N. S. Pelton, D. R. Tivey, G. S. Howarth, G. P. Davidson, and R. N. Butler, “A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat,” Scandinavian Journal of Gastroenterology, vol. 39, no. 10, pp. 1015–1016, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. K. L. Tooley, G. S. Howarth, and R. N. Butler, “Mucositis and non-invasive markers of small intestinal function,” Cancer Biology and Therapy, vol. 8, no. 9, pp. 753–758, 2009. View at Google Scholar · View at Scopus
  35. G. S. Howarth, G. L. Francis, J. C. Cool, X. Xu, R. W. Byard, and L. C. Read, “Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats,” Journal of Nutrition, vol. 126, no. 10, pp. 2519–2530, 1996. View at Google Scholar · View at Scopus
  36. L. P. Filaretova, T. R. Bagaeva, O. Y. Morozova et al., “The healing of NSAID-induced gastric lesion may be followed by small intestinal and cardiovascular side effects,” Journal of Physiology and Pharmacology, vol. 62, no. 6, pp. 619–625, 2011. View at Google Scholar
  37. L. Santucci, S. Fiorucci, F. M. Di Matteo, and A. Morelli, “Role of tumor necrosis factor α release and leukocyte margination in indomethacin-induced gastric injury in rats,” Gastroenterology, vol. 108, no. 2, pp. 393–401, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Murali, G. L. Milne, C. D. Webb et al., “Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR -/- mice,” The Journal of Lipid Research, vol. 53, no. 10, pp. 2186–2197, 2012. View at Publisher · View at Google Scholar
  39. G. Renier, E. Skamene, J. DeSanctis, and D. Radzioch, “Dietary n3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice: modulation of macrophage secretory activities,” Arteriosclerosis and Thrombosis, vol. 13, no. 10, pp. 1515–1524, 1993. View at Google Scholar · View at Scopus
  40. P. Yaqoob and P. Calder, “Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages,” Cellular Immunology, vol. 163, no. 1, pp. 120–128, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Ilic, D. Drmic, S. Franjic et al., “Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions,” Life Sciences, vol. 88, no. 11-12, pp. 535–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Mouzaoui, I. Rahim, and B. Djerdjouri, “Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice,” International Immunopharmacology, vol. 12, no. 1, pp. 302–311, 2012. View at Publisher · View at Google Scholar
  43. C. B. Herath, K. Mak, L. M. Burrell et al., “Angiotensin-(1-7) reduces the portal pressure response to angiotensin II and methoxamine via an endothelial nitric oxide mediated pathway in cirrhotic rat liver,” American Journal of Physiology Gastrointestinal and liver Physiology, vol. 304, no. 1, pp. G99–G108, 2012. View at Publisher · View at Google Scholar
  44. A. O. Abdel-Zaher, M. M. Abdel-Rahman, M. M. Hafez, and F. M. Omran, “Role of nitric oxide and reduced glutathione in the protective effects of aminoguanidine, gadolinium chloride and oleanolic acid against acetaminophen-induced hepatic and renal damage,” Toxicology, vol. 234, no. 1-2, pp. 124–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wakabayashi, T. Ito, S. Fushimi et al., “Spred-2 deficiency exacerbates acetaminophen-induced hepatotoxicity in mice,” Clinical Immunology, vol. 144, no. 3, pp. 272–282, 2012. View at Publisher · View at Google Scholar
  46. R. Valenzuela, A. Espinosa, D. Gonzalez-Manan et al., “N3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis,” PLoS ONE, vol. 7, no. 10, Article ID e46400, 2012. View at Publisher · View at Google Scholar
  47. D. C. Bennett, W. E. Code, D. V. Godin, and K. M. Cheng, “Comparison of the antioxidant properties of emu oil with other avian oils,” Australian Journal of Experimental Agriculture, vol. 48, no. 10, pp. 1345–1350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n6/n3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” Clinical Science, vol. 106, no. 6, pp. 635–643, 2004. View at Publisher · View at Google Scholar · View at Scopus